Journal article
Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
Abstract
The effect of recombinant human erythropoietin (EPO) on hospitalization of patients with end-stage renal disease (ESRD) was evaluated in a controlled clinical trial. A cohort of 67 new hemodialysis patients prescribed EPO shortly after the clinical availability of EPO were the treatment group. The control group was a cohort of 67 new hemodialysis patients matched for clinical center, age, cardiovascular disease and transfusion history. These …
Authors
Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
Journal
Clinical Nephrology, Vol. 43, No. 3, pp. 184–188
Publication Date
March 1995
ISSN
0301-0430